- Home
- NEGG vs ZURA Comparison
NEGG vs ZURA Comparison
Compare NEGG & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NEGG | ZURA |
|---|---|---|
| Founded | 2001 | 2022 |
| Country | United States | United States |
| Employees | 714 | N/A |
| Industry | Other Specialty Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 350.3M | 455.4M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | NEGG | ZURA |
|---|---|---|
| Price | $13.11 | $3.98 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | 41.3K | ★ 1.5M |
| Earning Date | 04-28-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.50 | $3.15 |
| 52 Week High | $96.29 | $7.25 |
Technical Indicators
Market Signals| Indicator | NEGG | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 36.28 | 27.36 |
| Support Level | $12.52 | $3.96 |
| Resistance Level | $14.98 | $5.87 |
| Average True Range (ATR) | 0.78 | 0.32 |
| MACD | -0.06 | -0.11 |
| Stochastic Oscillator | 8.17 | 7.21 |
Price Performance
Historical ComparisonAbout NEGG Newegg Commerce Inc.
Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home, and gaming products, and provides certain third-party logistics services globally. Geographically, it operates in the United States, Canada, and the Rest of the world.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.